
VYNE
Healthcare · Biotechnology · $19.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2026
EPS trend, 90 days to now · +18.2% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 18, 2026 | Time not confirmed | — | -0.08 | — |
| Feb 27, 2026 | Before the open | -11.50 | -5.50 | +52.2% |
| Nov 6, 2025 | Before the open | -6.50 | -8.50 | -30.8% |
| Aug 14, 2025 | Before the open | -11.17 | -6.50 | +41.8% |
| May 8, 2025 | Before the open | -14.50 | -10.00 | +31.0% |
| Feb 26, 2025 | Before the open | -0.30 | -0.28 | +7.0% |
| Nov 7, 2024 | Before the open | -11.75 | -14.50 | -23.4% |
| Aug 14, 2024 | Before the open | -9.50 | -11.00 | -15.8% |
| May 9, 2024 | Before the open | -0.24 | -0.15 | +37.5% |
| Feb 29, 2024 | Before the open | -25.00 | -10.00 | +60.0% |
| Nov 13, 2023 | Before the open | -38.00 | -100.50 | -164.5% |
| Aug 14, 2023 | Before the open | -129.00 | -154.50 | -19.8% |
| May 11, 2023 | After the close | -130.50 |
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low…
| -87.00 |
| +33.3% |
| Mar 9, 2023 | After the close | -3.24 | -3.33 | -2.8% |
| Nov 10, 2022 | After the close | -180.00 | -126.00 | +30.0% |
| Aug 12, 2022 | Before the open | -135.00 | -117.00 | +13.3% |
| May 12, 2022 | After the close | -2.97 | -2.52 | +15.2% |
| Mar 17, 2022 | Before the open | -231.00 | -180.00 | +22.1% |
| Nov 10, 2021 | Before the open | -290.25 | -324.00 | -11.6% |
| Aug 12, 2021 | Before the open | -318.60 | -315.54 | +1.0% |
| May 6, 2021 | Before the open | -358.20 | -333.00 | +7.0% |
| Mar 4, 2021 | Before the open | -9.60 | -9.90 | -3.1% |
| Nov 5, 2020 | Before the open | -540.00 | -540.00 | 0.0% |
| Aug 6, 2020 | Before the open | -747.00 | -496.80 | +33.5% |
| May 11, 2020 | Before the open | -2232.00 | -2264.04 | -1.4% |
| Mar 3, 2020 | After the close | -59.47 | -64.08 | -7.8% |
| Oct 31, 2019 | After the close | -55.56 | -50.40 | +9.3% |
| Aug 1, 2019 | After the close | -60.62 | -49.68 | +18.0% |
| May 2, 2019 | After the close | -58.18 | -58.32 | -0.2% |
| Feb 27, 2019 | After the close | -58.32 | -54.72 | +6.2% |
| Nov 7, 2018 | After the close | -63.79 | -40.32 | +36.8% |
| Aug 1, 2018 | After the close | -56.88 | -25.92 | +54.4% |
| May 9, 2018 | After the close | -47.88 | -51.84 | -8.3% |
| Mar 28, 2018 | After the close | -49.44 | -129.60 | -162.1% |